A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer

Purpose: To evaluate safety and preliminary efficacy of metronomic 5-fluorouracil plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with newly diagnosed metastatic pancreatic cancer (MPC). Methods: A total of 12 treatment-naive patients (aged 18–65 years, Eastern Coo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahai, Vaibhav, Saif, M. Wasif, Kalyan, Aparna, Philip, Philip A., Rocha-Lima, Caio M., Ocean, Allyson, Ondovik, Michael S., Simeone, Diane M., Banerjee, Sibabrata, Bhore, Rafia, Louis, Chrystal U., Picozzi, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761587/
https://www.ncbi.nlm.nih.gov/pubmed/31559379
http://dx.doi.org/10.1089/pancan.2019.0012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761587/
https://www.ncbi.nlm.nih.gov/pubmed/31559379
http://dx.doi.org/10.1089/pancan.2019.0012

Ejemplares similares